ArticleCancer discovery2013
The new kid on the block: RET in lung cancer.
Article in Cancer discovery, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- Thyroid C-Cell Biology and Oncogenic Transformation.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2025Review
- Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series.Clinical lung cancer · 2023Article
- Precious Gene: The Application of RET-Altered Inhibitors.Molecules (Basel, Switzerland) · 2022Review
- Profiling Receptor Tyrosine Kinase Fusions in Chinese Breast Cancers.Frontiers in oncology · 2021Article
- Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.ESMO open · 2020Article
- Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion.Therapeutic advances in medical oncology · 2020Review
- RET rearrangements are actionable alterations in breast cancer.Nature communications · 2018Article
- Biologic and Clinical Perspectives on Thyroid Cancer.The New England journal of medicine · 2016Review
- Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond.Translational lung cancer research · 2015Review
- Thyroid C-Cell Biology and Oncogenic Transformation.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2015Review
- New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RET has recently been identified as a potential new oncogenic driver in a subset of patients with non-small cell lung cancer (NSCLC). In this issue of Cancer Discovery, Drilon and colleagues report preliminary trial data with a RET inhibitor in RET fusion-positive NSCLC, validating RET as a therapeutic target in lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.